Posted on

MINDCURE Files Provisional Patent Application For iSTRYM, its Proprietary AI Digital Therapeutics (DTx) SaaS Platform, Designed To Enhance Effectiveness Of Psychedelic-Assisted Therapies For Practitioners And Patients

Company Now Is In Two High Growth Rate Global Markets With iSTRYM In The DTx Market, Projected To Reach $56 Billion By 2025 And The Global Psychedelic Market Projected To Reach Over $7.5 Billion By 2028

‍VANCOUVER, BC, Mar. 31, 2021 – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) an industry leader in advanced proprietary technology for psychedelic therapy, that also identifies, develops, and commercializes various proprietary  products that enhance mental health and wellness, ease suffering, and increase productivity, is pleased to announce that it has submitted a provisional patent application with the United States Patent and Trademark Office to cover iSTRYM, the company’s proprietary digital therapeutics (DTx) tool.

iSTRYM is an investigating technology that focuses on patient feedback and data-driven insights into the efficacy of treatments in order to assist in the application of more effective and more efficient diagnosis techniques and treatments. It’s a technology that is targeted for both therapists and patients.

MINDCURE is investing significant resources into its near term revenue strategy, developing the proprietary iSTRYM technology and digital therapeutics (DTx), targeting the value that these tools offer to the emerging markets of psychedelics and psychedelic-assisted therapy. DTx are evidence-based therapies delivered via software to complement existing treatments. What is unique about DTx compared to other health care technologies is that they require approval from regulatory bodies, unlocking the potential for insurer paid revenue streams. One approved by regulatory bodies, our technology and the fact based developed & more efficient therapies it gives birth to, will be adopted and utilized across a majority of practitioner therapists and patients, and become the service tool of choice. Its designed to be the model platform that becomes the industry backbone to identify and aggregate the best and most efficient protocols optimized by AI. It quantifies a number of therapies to create a universe of personalized and precision medical therapies identified in trials and individually recommended for each patient’s unique situation and needs.

iSTRYM will arm therapists with better tools and patient insights rooted in data while providing quantified care at scale to individuals who go through the therapeutic process.

“When people think of MINDCURE, I want them to see us as the leader in technology and specifically digital therapeutics for the psychedelics industry,” said Kelsey Ramsden, President and CEO, MINDCURE. “We intend to build iSTRYM into the world’s largest data repository of psychedelic experiences, backed by science and built on trust. This is why we were so thrilled to recently receive ethics approval from Veritas for our integration protocol research study, and why we view this provisional patent application as the next milestone for iSTRYM.” She continued: “Digital therapeutics (DTx) were gaining popularity as tools to help slash the $3 trillion annual spending (in the US alone) on chronic disease, and the pandemic has vaulted digital therapies into that spotlight. We are at the right place in time and  we believe that could bode well for our shareholders.”

‍

Pre-pandemic, the global DTx industry was projected to reach $13.8 billion in 2025 at a tremendous CAGR of 20.5 percent, but the increased acceptance and reliance on digital health care brought about by COVID-19 has increased this projection significantly, as new forecasts anticipate the DTx market to be a $56 billion global opportunity by 2025. 2

“We believe that iSTRYM has the potential to revolutionize the way mental health is treated across the world, and know the importance of patent protection as we invest significant resources in its development and commercialization,” said Geoff Belair, CTO, MINDCURE.

The patent application was submitted on March 22, 2021 as App. No. 63/167,611.

ABOUT iSTRYM

iSTRYM, a First-of-Its-Kind, AI-Driven Mental Wellness Optimization Tool. This  proprietary technology connects researchers, therapists, and individuals to achieve tangible results in mental health care. iSTRYM enables users to collect data, monitor progress, and connect to a network of support where the data can be the source of new procedures for practitioners and patients alike. iSTRYM enables psychedelic researchers to deliver results faster with cleaner data and deeper, richer insights. It also allows a built in distribution network to share commercialized proprietary protocols. iSTRYM also arms therapists with the most robust repository of science–backed treatment protocols and care practice packages ever compiled. Therapists can provide personalized care with deeper insights and long-tail support, while increasing clinic revenue, reducing clinic hours, and increasing positive patient outcomes. We believe that this will make therapies in general and customized individual therapies effectively evolve with more experience using our science–backed content with therapists and individuals around the world.  For more information go to: https://mindcure.com/tech/

__________________

‍

  1. 1, 2 https://www.databridgemarketresearch.com/reports/global-psychedelic-drugs-market

The Company also announces it has granted a total of 400,000 stock options to certain employees or consultants pursuant to the terms the Company’s incentive stock option plan (“Plan”). The stock options are exercisable at a price of $0.60 per share and subject to the terms of the Plan.

About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

‍

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: iSTRYM being the lynchpin for MINDCURE’s near-term revenue strategy; MINDCURE receiving a patent for iSTRYM; iSTRYM arming therapists with better tools and patient insights rooted in data while providing quantified care at scale to individuals who go through the therapeutic process; iSTRYM potentially becoming the world’s largest data repository of psychedelic experience; and iSTRYM revolutionizing the way mental health is treated across the world.

Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; iSTRYM will receive its full patent from the United States Patent and Trademark Office; and MINDCURE will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE’s industry and MINDCURE’s business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE’s investments, results of operations, financial condition, and MINDCURE’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments iSTRYM may not receive its full patent from the United States Patent and Trademark Office; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

Connect: Investor Relations: investors@mindcure.com; 1-888-593-8995

Jonathan L. Robinson CFA
Partner
Oak Hill Financial Inc.
jrobinson@oakhillfinancial.ca
416-669-1001

‍

Posted on

Ty Tashiro joins MINDCURE as the Senior Translational and Psychometric Architect for iSTRYM’s AI-Driven Psychedelic Digital Therapeutic Technology

The award-winning professor and psychology Ph.D. is an expert in translating psychological research and science into Artificial Intelligence backed real-world solutions

VANCOUVER, BC, March 19, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce the addition of Ty Tashiro as its new Senior Translational and Psychometric Architect for its iSTRYM digital therapeutics platform. In this new role, Ty will provide direction for the development of iSTRYM, and in particular how the platform captures and measures data inputs from therapists and patients and translates those inputs into effective psychedelic-assisted therapies and post-therapy integration.

“I started my career in academia with a strong research focus, and carried that into my professional career where I sought out opportunities to take proven psychological research and science and make it useful and relatable for people in their everyday lives,” said Ty Tashiro, MINDCURE’s  Senior Translational and Psychometric Architect. “I am excited with what MINDCURE is building with iSTRYM, and know the valuable role that technology can play as we work to scale metrics that meaningfully capture individuals’ unique experiences with psychedelic-assisted therapies.”

Ty earned his Ph.D. in psychology from the University of Minnesota and is a renowned expert in the field. He has published two books and won several awards for his teaching at both the University of Colorado and the University of Maryland. Outside of academia, he has held the role of Chief Science Officer and has relevant experience with the development and application of AI to solve real-world problems in psychology. His expertise in psychometrics, which is the measurement of psychological events, in particular, will be valuable to MINDCURE as it charts a new course for the psychedelics industry with iSTRYM.

“I strongly believe that near-term revenue in psychedelics is a key differentiator and Ty is a tremendous addition to the world-class team we continue to build for that execution. He has a deep understanding of the science and application of psychology to help people, and will add tremendous value and input as we look to build iSTRYM into the leading digital therapeutics platform for psychedelic-assisted therapies in the world,” said Kelsey Ramsden, President and CEO, MINDCURE. “His expertise in psychometrics will enable us to develop a strategy for reliable and valid client assessments and to create specific items and scales for proprietary use within iSTRYM. Our goal is to build iSTRYM into the trusted source that individuals turn to for science-backed, personalized mental health support at scale.”

Additionally, the Company has entered into an agreement with the Dales Report Inc. to provide services relating to a web series for a 6-month term beginning in March 2021. The Company has agreed to pay a total of CDN$45,000 for the services to be provided during the term.

About Ty Tashiro:

Ty Tashiro received his Ph.D. in psychology from the University of Minnesota and has been an award-winning professor at the University of Maryland and University of Colorado. He is also a published author, social scientist and relationship expert. His first book, THE SCIENCE OF HAPPILY EVER AFTER, shows how our decision-making abilities falter when it comes to choosing mates and how insights from social science can help us make smarter decisions. In AWKWARD: The Science of Why We’re Socially Awkward and Why That’s Awesome, he explains why some of the same characteristics that make people feel socially awkward can be the same traits that propel them toward extraordinary achievements.

In his professional career, Ty Tashiro also served as the Chief Science Officer at Connectidy, a platform that leveraged IBM’s Watson AI platform to improve decision-making at scale.

The Company also announces it has granted a total of 475,000 stock options to certain employees or consultants pursuant to the terms the Company’s incentive stock option plan (“Plan”). The stock options are exercisable at a price of $0.60 per share and subject to the terms of the Plan.

About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: Mr. Tashiro providing direction for the development of iSTRYM; Mr. Tashiro having relevant experience to MINDCURE and iSTRYM; near-term revenue being a key differentiator for MINDCURE; Mr. Tashiro adding a tremendous amount of value and input to MINDCURE; Mr. Tashiro’s expertise in psychometrics enabling the strategic development within iSTRYM; and iSTRYM becoming the trusted source that individuals turn to for mental health support at scale.”

Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; Mr. Tashiro will help MINDCURE to achieve its goals related to iSTRYM and with other potential technologies; MINDCURE will build iSTRYM into the leading digital therapeutics platform for psychedelic-assisted therapies in the world; and MINDCURE will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE’s industry and MINDCURE’s business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE’s investments, results of operations, financial condition, and MINDCURE’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; Mr. Tashiro may not help MINDCURE to develop iSTRYM or other potential technologies; iSTRYM may not become the trusted industry source for mental health support at scale; iSTRYM may not become the leading digital therapeutics platform for psychedelic-assisted therapies in the world; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at  www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

United States Advisory
The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), may be offered and sold outside the United States to eligible investors pursuant to Regulation S promulgated under the U.S. Securities Act, and may not be offered, sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in Regulation S under the United States Securities Act) unless the securities are registered under the U.S. Securities Act, or an exemption from the registration requirements of the U.S. Securities Act is available. Hedging transactions involving the securities must not be conducted unless in accordance with the U.S. Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States in which such offer, solicitation or sale would be unlawful.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

For further information: Connect: Investor Relations: investors@mindcure.com; 1-888-593-8995;  Jonathan L. Robinson CFA, Partner, Oak Hill Financial Inc., jrobinson@oakhillfinancial.ca,  416-669-1001

Posted on

MINDCURE Names Tarik Lebbadi as Chief Operating Officer

An accomplished international operator, Mr. Lebbadi led the medical division for Johnson & Johnson and has successfully scaled several high-growth companies

VANCOUVER, BC, March 15, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce that it has named Tarik Lebbadi as the Company’s new Chief Operating Officer, effective immediately. Mr. Lebbadi steps in to assume the role previously held by President & CEO Kelsey Ramsden. He is an accomplished international executive and operator with extensive experience in healthcare and technology, having served in a leadership position at Johnson & Johnson and at several high-growth technology companies. Most recently, he served in a strategic operational capacity at Aurora Cannabis through the industry’s legalization.

“I am thrilled to welcome Tarik to MINDCURE today,” said Kelsey Ramsden, President & CEO, MINDCURE. “With his diverse and relevant operational experience, he is the right leader to step in and drive our commercial team forward. His specific experience with Johnson & Johnson gives him an understanding of healthcare and the pace at which it operates, and he has significant hands-on experience with high-growth teams as well.”

Mr. Lebbadi began his career as a software engineer and has extensive operational experience with technology platforms. “Tarik’s specific software and technology experience will also be invaluable, both as an engineer and operator,” continued Mrs. Ramsden. “His experience with Johnson & Johnson aligns with MINDCURE’s strategy to be an integrated provider, from drug discovery through production and therapeutic support, with iSTRYM. His ability to drive strategy and execution across the board is a rare asset and one we are thrilled to have on our team.”

“I could not be more excited to join the MINDCURE team today,” said Tarik Lebbadi, COO, MINDCURE. “The company has an impressive vision and strategy in place, and I look forward to providing the commercial direction alongside Mrs. Ramsden. I have operated companies through all growth stages, from start-ups in technology to healthcare, and most recently in the cannabis industry through legalization. I believe that leading MINDCURE successfully will require lessons learned from all three, with our focus on proprietary technology, the importance of trust and science within healthcare, and establishing a culture of efficiency, focus, and compliance through growth and legalization. Perhaps most importantly, I am a passionate advocate of psychedelic medicines and believe in their potential to transform mental health care.”

About Tarik Lebbadi:

An accomplished executive within the healthcare and technology sectors, Mr. Lebbadi has over 13 years of international operational experience. He started his career as a software engineer but then moved to the business world to lead the medical division of Johnson & Johnson in Morocco. He later found a passion for scaling and structuring rapidly growing companies, and his most recent experience was in a strategic operational capacity at Aurora Cannabis through the industry’s legalization.

He holds a BA in Mathematics and Computer Science from Ripon College and an MBA from IESE Business School in Barcelona, Spain.

About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: Mr. Lebbadi driving MINDCURE’s commercial team forward; Mr. Lebbadi being the right leader for MINDCURE and his intended impact on MINDCURE; and Mr. Lebbadi helping to further the development and commercialization of iSTRYM.

Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; Mr. Lebbadi will help MINDCURE to achieve its goals as expected; and MINDCURE will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE’s industry and MINDCURE’s business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE’s investments, results of operations, financial condition, and MINDCURE’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; Mr. Lebbadi may not help MINDCURE to achieve its goals as expected; Mr. Lebbadi may not help the development and commercialization of iSTRYM; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

For further information: Connect: Investor Relations: investors@mindcure.com; 1-888-593-8995; Jonathan L. Robinson, CFA, Partner, Oak Hill Financial Inc., jrobinson@oakhillfinancial.ca, 416-669-1001

‍

Posted on

MINDCURE Receives Unconditional Ethics Approval for its Psychedelic Integration Protocol Research Study

This approval is a key step forward in the development of the company’s iSTRYM digital therapeutics platform.‍

VANCOUVER, BC, March 9, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce that it has received unconditional ethics approval from Veritas IRB for its integration protocol research study. This study will serve to inform the development of the company’s digital therapeutics platform, iSTRYM, and how it is built out to best serve therapists, patients and the entire psychedelics industry.

“This is a monumental milestone for MINDCURE and our digital therapeutics strategy,” said Kelsey Ramsden, President & CEO, MINDCURE. “As we build out iSTRYM to be the largest data repository of psychedelic experiences, we are ensuring that its development is rooted in research proof and a deep understanding of the systems and protocols provided during psychedelic therapy. This ethics approval from Veritas signifies both the scientific validation of this study, as well as the importance we place on building trust and integrity with both therapists and patients.”

“The impact of psychedelics is so vast that even subtle variations in approaches to integration can create a dramatic impact on a client’s trajectory,” said Dr. Mitch Earleywine, Professor of Psychology at The University at Albany, State University of New York and sub-investigator on this study for MINDCURE. “This work is bound to uncover important contributors to the best psychedelic-assisted therapy outcomes. Formal integration research is in its infancy, and traditional approaches haven’t lasted for centuries by accident. An intriguing experience is great, of course, but altering someone’s whole perspective can create gains that will continue to add to quality-of-life year after year.” Dr. Earleywine is also known for last year’s commentary underscoring the dire need for work like this study that appeared in Journal of Psychedelic Studies.1

Veritas Independent Research Board (IRB) is the first and only Canadian-owned and accredited central IRB. Known as a leader in research ethics, Veritas IRB has long been the research ethics board of choice for Canadian governmental departments, academic hospitals, regional hospitals, private research centers and non-governmental agencies conducting human research. Since its inception in 1996, its board has been dedicated to ensuring that its processes respect participants’ rights and that its services are delivered according to the highest standards of ethical and clinical practice.2

_________________________

Earleywine, M., & De Leo, J. (2020). Psychedelic-assisted psychotherapy for depression: How dire is the need? How could we do it?. Journal of Psychedelic Studies.
https://www.veritasirb.com/about-us.html
About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: MINDCURE’s psychedelic integration protocol research study informing the company’s development of iSTRYM; iSTRYM potentially becoming the largest data repository of psychedelic experiences; this study uncovering important contributors to the best psychedelic-assisted therapy outcomes; and that altering someone’s experience with psychedelics can create gains that will add quality of life year after year.

Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; this integration protocol research study will inform MINDCURE for the development of its iSTRYM platform; and MINDCURE will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE’s industry and MINDCURE’s business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE’s investments, results of operations, financial condition, and MINDCURE’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; this integration protocol research study may not inform MINDCURE for development of its iSTRYM platform; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

For further information: Connect: Investor Relations: investors@mindcure.com; 1-888-593-8995; Jonathan L. Robinson CFA, Partner, Oak Hill Financial Inc., jrobinson@oakhillfinancial.ca, 416-669-1001

Posted on

MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury

This potential treatment opportunity was confirmed by the company’s bioinformatics platform, PsyCollage

VANCOUVER, BC, Mar. 04, 2021 – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) a leader in developing technology to advance psychedelic-related treatments, is pleased to announce that the Company’s bioinformatics platform, PsyCollage, has identified opportunities for ibogaine to support neuroregenerative pathways that the Company believes could be pivotal in treating neuropathic pain and brain trauma.

Ibogaine is a psychoactive substance extracted from the iboga shrub native to West Africa. Contributing to its powerful anti-addiction actions, ibogaine is associated with increases in the levels of brain neurotrophic factors, particularly GDNF and BDNF, which have potent neuroregenerative and neuroprotective properties.1 Ibogaine is thought to repair and reset the brain’s reward system, facilitating detoxification in the context of addiction. In addition, it may stimulate the growth of new dopamine neurons, which further supports its therapeutic potential for neurodegenerative conditions such as Parkinson’s and Alzheimer’s disease.1

For these reasons, MINDCURE is synthesizing ibogaine, as announced in a news release dated March 3, 2021, to be used in the Company’s preclinical and clinical trials. Recently, the Company’s PsyCollage platform has identified the opportunity for the use of ibogaine to address neuropathic pain and brain trauma.

“PsyCollage ensures we are moving in the right direction in our mission to provide alternative and effective treatment options for psychological and physiological pain,” said Kelsey Ramsden, President & CEO, MINDCURE. “Ibogaine has centuries of therapeutic history reinforcing its potential to heal pain. As one of the first companies to manufacture synthetic ibogaine, we’re confident our research and development teams can help contribute to the drug’s uses and develop protocols that ultimately progress healing in Canada and around the world.”

Ibogaine has been used by West African communities for centuries in rituals and healing ceremonies. It was first introduced to the western world in 1864, and later marketed in France as a “neuromuscular stimulant” to combat fatigue, depression, and infectious disease between 1939-1970.2 The U.S. made possession of ibogaine illegal in 1967, and the U.S. FDA classified ibogaine as a schedule I drug in 1970, along with psilocybin and LSD. In Canada, Ibogaine was unregulated until 2017 when Health Canada added it to the Prescription Drug List, severely limiting legal access; however, more recently, the regulatory landscape is again becoming more favourable.

“Ibogaine’s therapeutic potential isn’t a new concept. MINDCURE’s bioinformatics platform, PsyCollage, however, gives us a starting point and a plethora of research to continue guiding us as we investigate ibogaine’s regenerative potential for healing, with a primary focus on brain trauma and neuropathic pain,” said Ryan Hartwell, Chief Scientific Officer, MINDCURE.

About PsyCollage

PsyCollage is MINDCURE’s proprietary bioinformatics platform used to direct MINDCURE’s research team in product discovery activities and decision-making. PsyCollage works by compiling predictive correlative statistical analytics from decades of documented clinical research. PsyCollage has developed into a turnkey resource for discovering target receptors and methods, managing clinical trial data, and mapping strategic business partnerships.

About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: the opportunities for ibogaine to support neuroregenerative pathways that MINDCURE believes could be pivotal in treating neuropathic pain and brain trauma; MINDCURE synthesizing ibogaine to be used in the Company’s preclinical and clinical trials; Ibogaine repairing and resetting the brain’s reward system, facilitating detoxification in the context of addiction, stimulating the growth of new dopamine neurons, and supporting neurodegenerative conditions such as Parkinson’s and Alzheimer’s disease; MINDCURE’s mission to provide alternative and effective treatment options for psychological and physiological pain; MINDCURE becoming one of the first companies to manufacture synthetic ibogaine, and contributing to the drug’s uses and develop protocols that ultimately progress healing in Canada and around the world.

Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; ibogaine’s ability to address neuropathic pain, neuroregeneration, and brain trauama will help MINDCURE achieve its research and business goals; and MINDCURE will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE’s industry and MINDCURE’s business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE’s investments, results of operations, financial condition, and MINDCURE’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; ibogaine’s ability to address neuropathic pain, neuroregeneration, and brain trauama will not help MINDCURE achieve its research and business goals; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

Connect: Investor Relations: investors@mindcure.com; 1-888-593-8995

Jonathan L. Robinson CFA
Partner
Oak Hill Financial Inc.
jrobinson@oakhillfinancial.ca
416-669-1001

1 Soledad Marton et al., “Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits,” Frontiers in Pharmacology 10 (May 2019), https://doi.org/10.3389/fphar.2019.00193.

2 Thomas Brown, “Ibogaine in the Treatment of Substance Dependence,” Current Drug Abuse Reviews 6, no. 1 (May 1, 2013): pp. 3, https://doi.org/10.2174/15672050113109990001.

‍

Posted on

MINDCURE Announces Manufacturing of Synthetic Ibogaine to be Used in Company’s Clinical Research

VANCOUVER, BC, Mar. 03, 2021 – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) a leader in advanced proprietary technology for psychedelic drug discovery, is pleased to announce that it has begun the first stage of manufacturing pharmaceutical grade ibogaine to be used in preclinical and clinical research.

Ibogaine is a naturally occurring psychoactive compound extracted from the root of the Tabernanthe iboga shrub, native of the Congo and Gabon.1 The compound offers therapeutic potential for substance use disorders, and is claimed to be among the most powerful anti-addiction drugs, particularly when used with proper supervision and support. However, natural sources of ibogaine are extremely limited since these plants are at risk of extinction due to the growing global demand and environmental pressures threatening their natural habitat.

MINDCURE recognizes the importance of sustainability, excellence, and reliability regarding the materials it uses in product development and research. By manufacturing ibogaine, MINDCURE’s research team will have access to a predictable and standardized supply of synthetic ibogaine, while ensuring consistent dosing and reliable results.

Ibogaine has unique and broad actions in the brain, affecting multiple receptors and neurotransmitter systems. In addition to inducing powerful subjective effects, research indicates ibogaine may help repair and rewire addiction-related neural pathways.2 Emerging evidence of its neuroprotective effects, as well as its ability to boost brain neurotrophic factors and neuroplasticity processes supports future research into the use of ibogaine and derivatives thereof for other indications, including in the treatment of neuropathic pain and neurodegenerative conditions, such as Parkinson’s and Alzheimer’s disease.3 While ibogaine showcases a wide mechanism of action, potential toxicity, and low bioavailability which may preclude ibogaine’s usefulness in treating neurodegenerative disorders, MINDCURE will dutifully design any research efforts in recognition of these facts.

“Ibogaine is among a few psychoactive alkaloids found in the iboga plant. Ibogaine offers incredible therapeutic potential, especially in the context of neuroregeneration,” said Dr. Ryan Hartwell, Chief Science Officer, MINDCURE. “Manufacturing ibogaine gives us the ability to pursue promising research avenues and obtain high-quality results, without threatening the existence of the plant and limiting the natural supply of an amazing psychedelic.”

About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: MINDCURE manufacturing ibogaine; ibogaine being used in MINDCURE’s preclinical and clinical trials; MINDCURE’s team generating a predictable supply of synthetic ibogaine to drive reliable results and consistent doses; and MINDCURE dutifully designing any research efforts in recognition of ibogaine’s wide mechanism of action, potential toxicity, and low bioavailability which may preclude ibogaine’s usefulness in treating neurodegenerative disorders.

Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; manufacturing ibogaine will help MINDCURE achieve its research goals; and MINDCURE will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE’s industry and MINDCURE’s business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE’s investments, results of operations, financial condition, and MINDCURE’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; manufacturing ibogaine may not help MINDCURE achieve its research goals; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

Connect: Investor Relations: investors@mindcure.com; 1-888-593-8995

Jonathan L. Robinson CFA
Partner
Oak Hill Financial Inc.
jrobinson@oakhillfinancial.ca
416-669-1001

1 Ignacio Carrera, “How the Psychedelic Ibogaine May Heal, Repair & Protect the Brain,” Chacruna (February 2018), https://chacruna.net/ibogaine-heal-repair-protect-brain/.

2 Soledad Marton et al., “Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits,” Frontiers in Pharmacology 10 (May 2019), https://doi.org/10.3389/fphar.2019.00193.

3 Soledad Marton et al., “Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits.”

Posted on

MINDCURE Completes Its Initial Strategic Equity Investment in ATMA, Canada’s First Commercial Provider of Legal, Psychedelic-Assisted, Therapy Utilizing Psilocybin

The completed equity investment strengthens ties between MINDCURE and ATMA.

VANCOUVER, BC, Mar. 2, 2021 – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in developing technology to advance psychedelic-related treatments, is pleased to announce the completion of its initial strategic equity investment of equal to approximately 13% ownership in ATMA Journey Centers Inc. (“ATMA“) in accordance with the terms of the letter of intent (the “LOI“) announced on January 12, 2021.

MINDCURE’s initial strategic investment of $500,000 will strengthen our relationship with Calgary-based private healthcare company, ATMA, which has recently provided psychedelic-assisted therapy sessions using psilocybin for patients with section 56 exemptions.1 MINDCURE will leverage the growing partnership with ATMA to secure a network of clinics in which to deploy and test MINDCURE’s iSTRYM platform, and concurrently,  provide MINDCURE with access to patient data accelerating the growth of iSTRYM‘s database. This will lead to better diagnoses, treatments and personalized care.

“Our partnership with ATMA represents a huge step forward for healing today in Canada and around the world. By accelerating the development of our research and technology platform, iSTRYM, we’re closer to minimizing the gaps that exist in health care, all the way from research to the deployment of care. It’s an amazing opportunity to innovate with pioneers of the psychedelic therapy industry by creating proprietary research, identifying commonalities, and driving real transformative results for individuals using psychedelic medicines,” said Kelsey Ramsden, President & CEO, MINDCURE.

Access to ATMA’s patient data will contribute to MINDCURE’s proprietary technology, iSTRYM, ultimately helping to optimize treatment for ATMA’s patients and providing a rich data resource for MINDCURE, in accordance with the LOI.

“As the first commercial company in Canada to announce legally treating a palliative patient with psychedelic-assisted therapy using psilocybin, we’re optimistic about the progression to better care options for Canadians. By partnering with MINDCURE, we’re enforcing consistency in terms of protocols, as well as the ability to automate patterns in our patients’ conditions. Overall, this will lead to better patient care, and a stronger foundation for this innovative and leading-edge industry,” said Greg Habstritt, President of ATMA Journey Centers Inc. “Our mission is to deliver effective and innovative healing and transformative experiences that leverage the compelling science around psychedelics. We’re committed to providing the resources, safeguards, expertise, and accessibility into insights that our work uncovers, in order to advocate for better care and new treatment options.”

About ATMA Journey Centers Inc.

ATMA is a private healthcare company with the mission of delivering effective and innovative healing and transformative experiences that awaken the inner healer and promote a deeper connection with the self, with others, and with the beauty of the world. ATMA was the first private sector service provider in Canada to announce conducting legal psychedelic-assisted therapy for a palliative care patient under the approval of Health Canada’s section 56(1) exemption.

The Company has granted a total of 300,000 stock options to certain employees or consultants pursuant to the terms the Company’s incentive stock option plan (“Plan”). The stock options are exercisable at a price of $0.63 per share and subject to the terms of the Plan.

About Mind Cure Health Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: strengthening relationship between MINDCURE and ATMA; securing a network of ATMA clinics and access to ATMA’s patient data to fuel MINDCURE’s digital therapeutics platform, iSTRYM; MINDCURE accessing a network of clinics to deploy and test iSTRYM; ATMA conducting further psychedelic-assisted therapy; iSTRYM and the relationship with ATMA leading to better diagnoses, treatments and personalized care; ATMA’s patient data enriching iSTRYM‘s database; acceleration of the development of iSTRYM.

Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; the partnership with ATMA will help MINDCURE achieve its business goals; ATMA will continue to grow and develop as a provider of clinical services; MINDCURE and ATMA will continue to expand their relationship and negotiate definitive agreements for data access and iSTRYM licensing; and MINDCURE will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE’s industry and MINDCURE’s business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE’s investments, results of operations, financial condition, and MINDCURE’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; MINDCURE’s partnership with ATMA may not help MINDCURE achieve its business goals; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

United States Advisory

The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), may be offered and sold outside the United States to eligible investors pursuant to Regulation S promulgated under the U.S. Securities Act, and may not be offered, sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in Regulation S under the United States Securities Act) unless the securities are registered under the U.S. Securities Act, or an exemption from the registration requirements of the U.S. Securities Act is available. Hedging transactions involving the securities must not be conducted unless in accordance with the U.S. Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States in which such offer, solicitation or sale would be unlawful.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

Connect: Investor Relations: investors@mindcure.com; 1-888-593-8995

Jonathan L. Robinson CFA
Partner
Oak Hill Financial Inc.
jrobinson@oakhillfinancial.ca
416 669 1001

1 “Exemptions,” The Government of Canada (Health Canada, November 13, 2020), https://www.canada.ca/en/health-canada/services/health-concerns/controlled-substances-precursor-chemicals/exemptions.html.

Posted on

Psychedelic Therapeutics Reviewed by NeuroPerspective

SAN DIEGO, March 2, 2021 /PRNewswire/ — NeuroPerspective has released its March/April 2021 issue, featuring its first-ever, comprehensive review of the rapidly-expanding Psychedelic Therapeutics space, where substances formerly relegated to sacramental and/or illegal status are being formally tested as treatments for CNS disorders. Psilocybin, LSD, DMT, 5-MeO-DMT are some of the ‘classic’ psychedelic substances being explored, along with ’empathogens’ like MDMA, dissociative drugs like ketamine, esketamine, arketamine, and a few substances less easily categorized, like ibogaine and its derivatives.

NI Research
NI Research

As NeuroPerspective publisher Harry Tracy PhD notes: “This is not a fallacy or fad, there is already substantial clinical support for the use of psychedelic drugs based on thousands of case-reports and small-scale studies. Now, much more rigorous studies are underway. Already, there is a compelling body of work supporting clinical value in PTSD (where MAPS has had a successful PhIII trial), Treatment-Resistant Depression (Compass Pathways currently is running a PhIIb study), Cancer-related Pain/Anxiety, and Addictions. Other areas, like Eating Disorders, Phantom-Limb Pain, Cancer Pain  and intractable migraines, and even cognitive disorders like ADHD and Alzheimer’s, are being assessed for the potential usefulness of psychedelics.”

 

The Review assesses close to fifty companies involved in psychedelics research: Including MAPS, Compass Pathways, ATAI Life Sciences and its panoply of partnered programs (Viridia, Perception Neuroscience, DeMeRx, Entheogenix, EmpathBio); MindMed,  Beckley Psytech, Field Trip Health, MindCure, Diamond Therapeutics, MYND, Gilgamesh Pharma, Cybin, PsyBio, Small Pharma, Mindset,  Tactogen, Usona Institute, Entheon Biomedical, Eleusis, and many more. These companies cover the gamut of skillsets and viability, from well-founded to ephemeral pipedreams. The rationale for psychedelic mechanisms (e.g. classic 5HT-2a binding, impact on default mode networks) are reviewed, factors governing the path forward for the class are examined in detail.

Despite the numerous books, papers, and conferences that have sprung up in the past two to three years, no publication combines insights into the science, medical, and business underpinnings of the new wave of Psychedelics Therapeutics, and frank assessments of their prospects, like NeuroPerspective provides with this release.

The issue also includes a Company Spotlight appraisal of MindMed; a brief discussion regarding the aducanumab PDUFA extension, and coverage of six Alzheimer’s programs and their clinical news, including Cassava Sciences, Cortexyme, Lilly, and Biohaven.

The report contains 43 pages.

About NI Research

NI Research is the leading publisher of independent research on the neurotherapeutics industry, and has developed an unmatched information base regarding both publicly and privately held CNS companies.

A one-year (1-5 user) subscription to NeuroPerspective is $2900. A 6-10 user subscription is $4950. Other customized userbase and startup pricing options are available.

The March/April issue covering Psychedelic Therapeutics is being made available as a single-issue purchase, for $750.

NI Research has just released the 2021 edition of NeuroLicensing, which comprehensively reviews current licensing trends in the CNS area, and assesses large and midsize pharma companies in terms of their licensing agendas and performance.

NI Research’s Second Opinion provides consulting services to the pharma industry on strategic direction and licensing.

Further information and online purchasing with immediate downloads are available at http://www.niresearch.com/onlinestore.html.

Harry M. Tracy PhD
760.753.6376
304196@email4pr.com

SOURCE NI Research

Posted on

MINDCURE Announces Official Release of Nootropic and Adaptogen Products, Available on E-Commerce Platform

MINDCURE’s first items in a line of original supplements, including Reishi Energy , Lion’s Mane Focus, Turkey Tail Immunity, and Teen, available for purchase.

VANCOUVER, BC, Feb. 18, 2021 – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) is pleased to announce the release of its original nootropic and adaptogen product offerings (the “Products”). Items can now be ordered from the Company’s website and are expected to begin shipping Feb. 23.

“Our supplements launch marks the beginning of MINDCURE’s product sales division, which is a key milestone for the company this year. With it, we’re promoting support across the spectrum of mental hygiene to the general public,” said Sacha Hebbert, Senior Product & Marketing Manager, MINDCURE. “MINDCURE’s nootropic and adaptogen products are safe, unique, and packed with all-natural ingredients specifically chosen to promote mental performance. We’re eager to continue developing our product offerings to help in new and exciting ways.”

MINDCURE’s first Products in an ever-expanding line of mental hygiene and wellness offerings include three nootropic formulations in capsule and powder form, as well as a teen-centric formulation in capsule form:

  • MINDCURE Lion’s Mane Focus
  • MINDCURE Reishi Energy
  • MINDCURE Turkey Tail Immunity
  • MINDCURE Teen

MINDCURE’s overall mission is to improve wellness, so people can maintain mental health and achieve mental wealth. Our first step is promoting mental hygiene to help customers tackle their day-to-day list of demands with added energy, focus, and protection from immune threats,” said Kelsey Ramsden, President & CEO, MINDCURE. “We know that trust is essential when building out products used to optimize mental wellbeing. I am thrilled that our team is committed to ensuring exemplary quality standards with all our natural products.”

About MINDCURE’s Products

MINDCURE harnesses the benefits of nootropic mushrooms and adaptogens, which are known to support the immune system, boost energy, and balance mood by confronting sleeplessness, restlessness, distractedness, and brain fog.

MINDCURE’s current nootropic formulations contain 100% organic, sustainably cultivated functional mushrooms. MINDCURE’s Teen formulation comprises safe, all-natural ingredients including botanicals, minerals, and vitamins known to reduce nervousness, sleeplessness, and restlessness in teens. Notably, Teen meets the standards laid out by California’s Proposition 65, which ensures products do not contain harmful levels of hazardous chemicals.1

About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE drives to reinvent the mental health care industry for patients and practitioners.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. The Company is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: MINDCURE’s intention of releasing the Products; MINDCURE’s Products shipping Feb. 23, 2021; MINDCURE expanding its nootropic and adaptogen products; and MINDCURE’s mission to improve overall wellness and mental hygiene.

Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; the release of MINDCURE’s Products will help MINDCURE achieve its business goals; and MINDCURE will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE’s industry and MINDCURE’s business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE’s investments, results of operations, financial condition, and MINDCURE’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; the release of MINDCURE’s Products may not help MINDCURE achieve its business goals; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health (MINDCURE) Inc.

For Further Information: Investor Relations: investors@mindcure.com; 1-888-593-8995

1 “About Proposition 65.” California Office of Environmental Health Hazard Assessment. OEHHA. Accessed December 24, 2020. https://oehha.ca.gov/proposition-65/about-proposition-65.